Garantziotis, Panagiotis published the artcileMolecular taxonomy of systemic lupus erythematosus through data-driven patient stratification: molecular endotypes and cluster-tailored drugs, Application In Synthesis of 377727-87-2, the publication is Frontiers in Immunology (2022), 860726, database is CAplus and MEDLINE.
Treatment of Systemic Lupus Erythematosus (SLE) is characterized by a largely empirical approach and relative paucity of novel compound development. We sought to stratify SLE patients based on their mol. phenotype and identify putative therapeutic compounds for each mol. fingerprint. By the use of whole blood RNA-seq data from 120 SLE patients, and in a data-driven, clin. unbiased manner, we established modules of commonly regulated genes (mol. endotypes) and re-stratified patients through hierarchical clustering. Disease activity and severity were assessed using SLEDAI-2K and Lupus Severity Index, resp. Through an in silico drug prediction pipeline, we investigated drugs currently in use, tested in lupus clin. trials, and listed in the iLINCS prediction databases, for their ability to reverse the gene expression signatures in each mol. endotype. Drug repurposing anal. was also performed to identify perturbagens that counteract group-specific SLE signatures. Mol. taxonomy identified five lupus endotypes, each characterized by a unique gene module enrichment pattern. Neutrophilic signature group consisted primarily of patients with active lupus nephritis, while the B-cell expression group included patients with constitutional features. Patients with moderate severity and serol. activity exhibited a signature enriched for metabolic processes. Mild disease was distributed in two groups, exhibiting enhanced basic cellular functions, myelopoiesis, and autophagy. Bortezomib was predicted to reverse disturbances in the “neutrophilic” cluster, azathioprine and ixazomib in the “B-cell” cluster, and fostamatinib in the “metabolic” patient subgroup. The clin. spectrum of SLE encompasses distinct mol. endotypes, each defined by unique pathophysiol. aberrancies potentially reversible by distinct compounds
Frontiers in Immunology published new progress about 377727-87-2. 377727-87-2 belongs to triazoles, auxiliary class GPCR/G Protein,Adenosine Receptor, name is 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, and the molecular formula is C25H29N9O3, Application In Synthesis of 377727-87-2.
Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics